Commercial Supply Molnupiravir and Related Intermediates with High Quality
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Chemical Name | Molnupiravir N-1 |
| Synonyms | ((3aR,4R,6R,6aR)-6-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate; Molnupiravir Intermediate; Molnupiravir Dimethyl Dioxol Impurity; Molnupiravir Impurity 11 |
| CAS Number | 2346620-55-9 |
| CAT Number | RF-PI310 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C16H23N3O7 |
| Molecular Weight | 369.37 |
| Solubility | Soluble in DMSO |
| Density | 1.51±0.1 g/cm3 |
| Shipping Temperature | Ambient |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| Loss on Drying | ≤1.0% |
| Residue on Ignition | ≤0.20% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤2.0% |
| Heavy Metals | ≤20ppm |
| Purity | ≥98.0% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Molnupiravir (CAS 2349386-89-4) COVID-19 |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Molnupiravir N-1 (CAS 2346620-55-9), is the intermediate of Molnupiravir (CAS 2349386-89-4) in treatment of COVID-19. Molnupiravir (EIDD-2801) is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever. Molnupiravir (EIDD-2801) is efficiently hydrolyzed in vivo after absorption, resulting in detection of only free NHC in plasma. EIDD-2801 robustly reduces MERS-CoV infectious titers, viral RNA, and pathogenesis under both prophylactic and early therapeutic conditions. Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.